Site icon Market Globalist

Blistering updated pushed Exicure, Inc. (XCUR), stock downwards in the premarket

GMVD Stock

GMVD Stock

Exicure, Inc. (Nasdaq: XCUR), plunged -9.52% to $1.9 in the premarket session after a pharmaceutical leader in novel biopharmaceuticals incorporating spherical nucleic acids, today announced that U.S. Patent and Trademark Office has issued two new patents, No.10,792,251 (the ‘251 patent) and No. 10,837,018 (the ‘018 patent), and allowed U.S. patent application 14/907,430 (the ‘430 application), further strengthening the Company’s patent portfolio and coverage for cavrotolimod.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

Discover Tomorrow's Stocks Today!

When it comes to discovering hidden gems within the stock market, Stock Wire News has consistently provided invaluable insights. Stock Wire News invites you to explore their upcoming Wealth Building Report. This report will shine a spotlight on little-known companies with the potential for substantial growth in 2024, and it's completely FREE for a limited time.

Claim the free report now by clicking here and start discovering the hidden gems of the market
Sponsored

The ‘018 patent and the’ 430 application, all entitled,’ Spherical Nucleic Acid-based Structures as Prophylactic and Therapeutic Immunostimulatory Agents,’ cover nanoparticles a corona of CpG oligonucleotides and their cancer therapy techniques.

Read More

The ‘251 patent, jointly held by the Company and Northwestern University, is guided to liposomal nanoparticles with toll-like receptor 9 (TLR9) agonist oligonucleotides and cancer treatment methods, entitled,’ Liposomal Particles, Methods of Producing Same and Uses Thereof.’